RxDoctor Payments Data

Nancy Frappier, MD

Neurology · Kokomo, INNPI 1598762510

Payments from drug & device makers

$1,218in general payments, 2019–2025

Across 61 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$207
  • Sanofi$115
  • Biogen$110
  • Novartis$107
  • Eisai Inc.$88
  • Sunovion Pharmaceuticals Inc.$85
  • plus $506 from 18 others

What the payments were for

  • Food & beverage$1,19398%
  • Education$242%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,218 in reported general payments places this provider in the 40th percentile of 308 neurology providers in Indiana.

See all neurology providers in Indiana

Medicare billing

Part B allowed, 2024
$130,344
Medicare patients
672
Services billed
1,056

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab31$334,029
Teriflunomide78$174,722
AubagioTeriflunomide12$111,761
Plegridy PenPeginterferon Beta-1a12$93,151
QuliptaAtogepant73$89,928
Glatiramer Acetate37$81,393
NuedextaDextromethorphan Hbr/Quinidine36$75,153
AptiomEslicarbazepine Acetate45$60,791
UbrelvyUbrogepant54$57,146
FycompaPerampanel40$52,027
Emgality PenGalcanezumab-Gnlm48$39,530
FingolimodFingolimod Hcl27$38,533
EliquisApixaban32$35,419
Nurtec OdtRimegepant Sulfate18$25,544
Lacosamide156$22,419

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy, Namzaric$207$167,151142 claims
SanofiAubagio$115$111,76112 claims
Avanir Pharmaceuticals, Inc.Nuedexta$68$75,15336 claims
PfizerEliquis, Nurtec Odt$17$60,96350 claims
Sunovion Pharmaceuticals Inc.Aptiom$85$60,79145 claims
Eisai Inc.Fycompa$88$52,02740 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 308 neurology providers in Indiana.

Other neurology in Kokomo

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →